Goldman Sachs Group set a €79.00 ($91.86) price objective on Sanofi (EPA:SAN) in a research report sent to investors on Wednesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. upgraded shares of ROYAL MAIL PLC/ADR from an underweight rating to a neutral rating in a research report on Monday, June 3rd. UBS Group restated a hold rating and issued a $7.80 price objective on shares of Deutsche Bank in a research report on Friday, April 26th. HSBC restated a buy rating and issued a price objective on shares of Deutsche Telekom in a research report on Tuesday, June 11th. Jefferies Financial Group restated a buy rating on shares of Linde in a research report on Friday, June 21st. Finally, Deutsche Bank restated a buy rating and issued a $80.00 price objective on shares of Bayerische Motoren Werke in a research report on Monday, July 8th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Sanofi has a consensus rating of Buy and an average price target of €85.47 ($99.38).

Shares of SAN opened at €74.57 ($86.71) on Wednesday. Sanofi has a fifty-two week low of €63.09 ($73.36) and a fifty-two week high of €92.97 ($108.10). The business’s 50-day simple moving average is €75.97.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Further Reading: Bollinger Bands

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.